Swift Health Systems said yesterday that it raised $45 million in Series C funding for the commercialization of its Inbrace orthodontics.
The Inbrace aligner is designed to use an all-digital platform with wire and bracket designs to dictate a path for tooth movements, resulting in efficiency and reduced treatment time. Inbrace Smartwires are programmed with data from digital scans of teeth and automate steps in the orthodontic treatment.
Vivo Capital, Novo Holdings and venBio Partners co-led the round. Vivo Capital principal Dr. Andrew Goldberg, Novo Ventures partner Peter Moldt and venBio partner Dr. Aaron Royston are also slated to join the Swift Health board, according to a news release.
Irvine, Calif.-based Swift Health said the Series C round brings its total capital raise to more than $70 million.
“Inbrace is a real game-changer, and this latest funding will help us ensure that every Inbrace provider can finally give their patients what they’ve always wanted – a truly invisible journey to a great new smile that is convenient and shows immediate results,” Swift Health CEO & co-founder Dr. John Pham said in prepared remarks. “Even with [do it yourself] orthodontic therapy on the rise, most consumers appreciate the benefits of supervised healthcare from a licensed professional. Inbrace keeps patient care in the hands of clinicians, where the overall patient experience, oral health and treatment results are always top priorities.”
“Vivo is delighted to join the Swift Health Systems team,” added Goldberg. “We believe that the advanced technologies behind Inbrace truly invisible braces will revolutionize the future of orthodontic treatment. The capital raised will enable Swift to advance the ways it supports patients and orthodontists around the globe.”